Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion, and Pharmacokinetics

/Home/Lyophilization Articles & Reports

Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion, and Pharmacokinetics
July 2003
Jordi Riba, Marta Valle, Gloria Urbano, Mercedes Yritia, Adelaida Morte, and Manel J. Barbanoj
Journal of Pharmacology And Experimental Therapeutics JPET 306:73-83, 2003
Please visit the web site to view the article in its entirety.
Abstract
The effects of the South American psychotropic beverage ayahuasca on subjective and cardiovascular variables and urine monoamine metabolite excretion were evaluated, together with the drug's pharmacokinetic profile, in a double-blind placebo-controlled clinical trial. This pharmacologically complex tea, commonly obtained from Banisteriopsis caapi and Psychotria viridis, combines N,N-dimethyltryptamine (DMT), an orally labile psychedelic agent showing 5-hydroxytryptamine2A agonist activity, with monoamine oxidase (MAO)-inhibiting {beta}-carboline alkaloids (harmine, harmaline, and tetrahydroharmine). Eighteen volunteers with prior experience in the use of psychedelics received single oral doses of encapsulated freeze-dried ayahuasca (0.6 and 0.85 mg of DMT/kg of body weight) and placebo. Ayahuasca produced significant subjective effects, peaking between 1.5 and 2 h, involving perceptual modifications and increases in ratings of positive mood and activation. Diastolic blood pressure showed a significant increase at the high dose (9 mm Hg at 75 min), whereas systolic blood pressure and heart rate were moderately and nonsignificantly increased. Cmax values for DMT after the low and high ayahuasca doses were 12.14 ng/ml and 17.44 ng/ml, respectively. Tmax (median) was observed at 1.5 h after both doses. The Tmax for DMT coincided with the peak of subjective effects. Drug administration increased urinary normetanephrine excretion, but, contrary to the typical MAO-inhibitor effect profile, deaminated monoamine metabolite levels were not decreased. This and the negligible harmine plasma levels found suggest a predominantly peripheral (gastrointestinal and liver) site of action for harmine. MAO inhibition at this level would suffice to prevent first-pass metabolism of DMT and allow its access to systemic circulation and the central nervous system.
References
Anonymous (2000) L'Ayahuasca: de l'Amazonie ? la Jungle Urbaine, in La G?opolitique Mondiale des Drogues 1998/1999, pp 102?106, Observatoire G?opolitique des Drogues, Paris.
Brawley P and Duffield JC (1972) The pharmacology of hallucinogens. Pharmacol Rev 24: 31?66
Buckholtz NS and Boggan WO (1977) Monoamine oxidase inhibition in brain and liver produced by {beta}-carbolines: structure-activity relationships and substrate specificity. Biochem Pharmacol 26: 1991?1996
Callaway JC, McKenna DJ, Grob CS, Brito GS, Raymon LP, Poland RE, Andrade EN, Andrade EO, and Mash DC (1999) Pharmacokinetics of hoasca alkaloids in healthy humans. J Ethnopharmacol 65: 243?256.
Callaway JC, Raymon LP, Hearn WL, McKenna DJ, Grob CS, Brito GC, and Mash DC (1996) Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with Ayahuasca. J Anal Toxicol 20: 492?497.
Cam? J, Farr? M, Mas M, Roset PN, Poudevida S, Mas A, San L, and de la Torre R (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects. J Clin Psychopharmacol 20: 455?466.
de la Torre R, Farr? M, Roset PN, Hern?ndez L?pez C, Mas M, Ortu?o J, Menoyo E, Pizarro N, Segura J, and Cam? J (2000) Pharmacology of MDMA in humans. Ann NY Acad Sci 914: 225?237.
Dobkin de Rios M (1984) Visionary Vine: Hallucinogenic Healing in the Peruvian Amazon. Waveland Press, Prospect Heights, IL.
Dobkin de Rios M (1996) Commentary on "Human pharmacology of Hoasca": a medical anthropology perspective. J Nerv Ment Dis 184: 95?98.
Farr? M, de la Torre R, Llorente M, Lamas X, Ugena B, Segura J, and Cam? J (1993) Alcohol and cocaine interactions in humans. J Pharmacol Exp Ther 266: 1364?1373
Farr? M, Ter?n MT, Roset PN, Mas M, Torrens M, and Cam? J (1998) Abuse liability of flunitrazepam among methadone-maintained patients. Psychopharmacology 140: 486?495
Gamache PH, Kingery ML, and Acworth IN (1993) Urinary metanephrine and normetanephrine determined without extraction by using liquid chromatography and coulometric array detection. Clin Chem 39: 1825?1830.
Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar KA, Lindenblatt H, Hermle L, Spitzer M, and Sass H (1999) Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Psychopharmacology 142: 41?50.
Grob CS, McKenna DJ, Callaway JC, Brito GS, Neves ES, Oberlaender G, Saide OL, Labigalini E, Tacla C, Miranda CT, et al. (1996) Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis 184: 86?94.[
Hollister LE and Moore F (1967) Urinary catecholamine excretion following lysergic acid diethylamide in man. Psychopharmacologia 11: 270?275.
Koulu M, Scheinin M, Kaarttinen A, Kallio J, Pyykk? K, Vuorinen J, and Zimmer RH (1989) Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. Br J Clin Pharmacol 27: 243?255.
Lamas X, Farr? M, Llorente M, and Cam? J (1994) Spanish version of the 49-item short form of the Addiction Research Center Inventory. Drug Alcohol Depend 35: 203?209.
Martin WR, Sloan JW, Sapira JD, and Jasinski DR (1971) Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin Pharmacol Ther 12: 245?258.
Mas M, Farr? M, de la Torre R, Roset PN, Ortu?o J, Segura J, and Cam? J (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290: 136?145.
McKenna DJ, Towers GHN, and Abbott F (1984) Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and {beta}-carboline constituents of ayahuasca. J Ethnopharmacol 10: 195?223.
Messiha FS and Grof S (1973) D-Lysergic acid diethylamide (LSD)?effect on biogenic amines excretion in man. Biochem Pharmacol 22: 2352?2354.
Ott J (1999) Pharmahuasca: human pharmacology of oral DMT plus harmine. J Psychoact Drugs 31: 171?177.
Parker NC, Levtzow CB, Wright PW, Woodard LL, and Chapman JF (1986) Uniform chromatographic conditions for quantifying urinary catecholamines, metanephrines, vanillylmandelic acid, 5-hydroxyindoleacetic acid, by liquid chromatography, with electrochemical detection. Clin Chem 32: 1473?1476.
Pierce PA and Peroutka SJ (1989) Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology 97: 118?122.
Pletscher A (1966) Monoamine oxidase inhibitors. Pharmacol Rev 18: 121?129.
Riba J, Rodr?guez-Fornells A, Strassman RJ, and Barbanoj MJ (2001a) Psychometric assessment of the Hallucinogen Rating Scale. Drug Alcohol Depend 62: 215?223.
Riba J, Rodr?guez-Fornells A, Urbano G, Morte A, Antonijoan R, Montero M, Callaway JC, and Barbanoj MJ (2001b) Subjective effects and tolerability of the South American psychoactive beverage ayahuasca in healthy volunteers. Psychopharmacology 154: 85?95.
Rivier L and Lindgren JE (1972) "Ayahuasca", the South American hallucinogenic drink: an ethnobotanical and chemical investigation. Econ Bot 26: 101?129.
Schultes RE and Hofmann A (1980) The Botany and Chemistry of Hallucinogens. Charles C. Thomas, Springfield, IL.
Schultes RE and Hofmann A (1982) Plantas de los dioses: or?genes del uso de los alucin?genos. Fondo de Cultura Econ?mica, M?xico D. F.
Slotkin TA, DiStefano V, and Au WYW (1970) Blood levels and urinary excretion of harmine and its metabolites in man and rats. J Pharmacol Exp Ther 173: 26?30.
Smith RL, Canton H, Barrett RJ, and Sanders-Bush E (1998) Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors. Pharmacol Biochem Behav 61: 323?330.
Soldin SJ and Hill JG (1980) Simultaneous liquid-chromatographic analysis for 4-hydroxy-3-methoxymandelic acid and 4-hydroxy-3-methoxyphenylacetic acid in urine. Clin Chem 26: 291?294.
Spielberger CD, Gorsuch RL, and Lushene RE (1970) Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, Palo Alto.
Strassman RJ (1994) Human psychopharmacology of LSD, dimethyltryptamine and related compounds, in 50 Years of LSD: Current Status and Perspectives of Hallucinogens (Pletscher A and Ladewig D eds) pp 145?174, Parthenon, London.
Strassman RJ and Qualls CR (1994) Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic and cardiovascular effects. Arch Gen Psychiatry 51: 85?97.
Strassman RJ, Qualls CR, Uhlenhuth EH, and Kellner R (1994) Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51: 98?108.
Suzuki O, Katsumata Y, and Oya M (1981) Characterization of eight biogenic indoleamines as substrates for type A and type B monoamine oxidase. Biochem Pharmacol 30: 1353?1358.
Yritia M, Riba J, Ortu?o J, Ramirez A, Castillo A, Alfaro Y, de la Torre R, and Barbanoj MJ (2002) Determination of N,N-dimethyltryptamine and {beta}-carboline alkaloids in human plasma following oral administration of Ayahuasca. J Chromatogr Biomed Appl 779: 271?281.
Yu A, Idle JR, Krausz KW, Kupfer A, and Gonzalez FJ (2003) Contribution of individual cytochrome P450 isoenzymes to the O-demethylation of the psychotropic {beta}-carboline alkaloids harmaline and harmine. J Pharmacol Exp Ther 305: 315?322.